Licensing status

Publication and contact information

Drug platforms

Predicting transplant rejection with a universal, common rejection module

Computational analysis of gene expression data from organ transplant patients identified an 11-gene signature that correlated with acute transplant rejection. In biopsies from a cohort of 120 renal transplant recipients, the signature predicted future transplant rejection in symptomless patients. In a mouse cardiac transplant model, Lipitor atorvastatin or Sprycel dasatinib, which reduced the levels or activity of different components of the signature, decreased the number of graft-infiltrating CD8+ T cells and increased transplant survival compared with no treatment. Next steps include validating the signature and immune benefits conferred by Lipitor on transplant survival in prospective clinical trials.
Pfizer Inc. markets the HMG-CoA reductase inhibitor Lipitor to treat hypercholesterolemia, stroke, coronary artery disease (CAD), myocardial infarction (MI) and other cardiovascular indications.
Bristol-Myers Squibb Co. markets the tyrosine kinase inhibitor Sprycel to treat hematopoietic cancers.

SciBX 6(44); doi:10.1038/scibx.2013.1277
Published online Nov. 14, 2013

Patent applications filed by Stanford University; available for licensing

Khatri, P. et al. J. Exp. Med.; published online Oct. 14, 2013;
Contact: Minnie M. Sarwal, Stanford University, Stanford, Calif.